Hemogenyx Pharmaceuticals PLC (HEMO) — Cash Flow-to-Debt Ratio
Hemogenyx Pharmaceuticals PLC (HEMO) has a Cash Flow-to-Debt Ratio of -0.53x as of December 2024, meaning its operating cash flow of GBX-1.78 Million could theoretically repay -1% of its total liabilities (GBX3.36 Million) in one year. Check total reinvestment intensity of Hemogenyx Pharmaceuticals PLC to assess the company's total reinvestment commitment from operating cash flow.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Hemogenyx Pharmaceuticals PLC Cash Flow-to-Debt Ratio (2015–2024)
Historical debt coverage capacity for Hemogenyx Pharmaceuticals PLC across 10 annual periods. Also explore Hemogenyx Pharmaceuticals PLC total assets for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Hemogenyx Pharmaceuticals PLC (2015–2024)
Year-by-year debt coverage analysis for Hemogenyx Pharmaceuticals PLC. For market capitalisation and broader financial context, see Hemogenyx Pharmaceuticals PLC (HEMO) market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (GBX) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -1.23x | GBX-4.12 Million | GBX3.36 Million | ▲ +33.2% |
| 2023 | -1.84x | GBX-6.11 Million | GBX3.32 Million | ▼ -142.8% |
| 2022 | -0.76x | GBX-2.91 Million | GBX3.85 Million | ▲ +89.8% |
| 2021 | -7.45x | GBX-2.63 Million | GBX352.84K | ▼ -640.7% |
| 2020 | -1.01x | GBX-1.80 Million | GBX1.79 Million | ▼ -17.2% |
| 2019 | -0.86x | GBX-1.20 Million | GBX1.40 Million | ▲ +15.0% |
| 2018 | -1.01x | GBX-1.35 Million | GBX1.34 Million | ▲ +41.3% |
| 2017 | -1.72x | GBX-452.98K | GBX263.69K | ▲ +11.3% |
| 2016 | -1.94x | GBX-278.15K | GBX143.69K | ▼ -599506.7% |
| 2015 | 0.00x | GBX79.71 | GBX246.83K | — |